Article Text

Download PDFPDF

Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis
  1. Marloes W Heijstek1,
  2. Gecilmara C S Pileggi1,2,
  3. Evelien Zonneveld-Huijssoon1,
  4. Wineke Armbrust3,
  5. Esther P A H Hoppenreijs4,
  6. Cuno S P M Uiterwaal5,
  7. Wietse Kuis1,
  8. Nico M Wulffraat1
  1. 1
    Department of Paediatric Immunology, Wilhelmina Children’s Hospital, University Medical Centre Utrecht, PO Box 85090, 3508 AB Utrecht, The Netherlands
  2. 2
    Department of Paediatric Rheumatology and immunology, School of Medicine of Ribeirão Preto, University of Sao Paulo, Brasil
  3. 3
    Department of Paediatric Rheumatolgy, Beatrix Children’s Hospital, University Medical Centre Groningen, The Netherlands
  4. 4
    Department of Paediatrics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
  5. 5
    Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, The Netherlands
  1. N M Wulffraat, Department of Paediatric Immunology, Wilhelmina Children’s Hospital, University Medical Centre Utrecht, Room KC 03-0630, PO Box 85090, 3508 AB Utrecht, The Netherlands; n.wulffraat{at}umcutrecht.nl

Abstract

Objective: To assess the effect of measles, mumps and rubella (MMR) vaccination on disease activity in children with juvenile idiopathic arthritis (JIA).

Methods: A retrospective observational multicentre cohort study was performed in 314 patients with JIA, born between 1989 and 1996. Disease activity and medication use were compared during the period of 6 months before vaccination versus 6 months after vaccination. Disease activity was measured by joint counts, the Physician’s global assessment scale and erythrocyte sedimentation rate. Next, we compared disease activity in patients vaccinated between 8 and 9 years of age with the activity in patients who had not been vaccinated at this time (who received MMR between the ages of 9 and 10 years).

Results: No increase in disease activity or medication use was seen in the 6 months after MMR vaccination (n = 207), including in patients using methotrexate (n = 49). No overt measles infections were noted. When disease activity in vaccinated patients (n = 108) was compared with activity in those not yet vaccinated (n = 86), there were no significant differences.

Conclusions: The MMR booster vaccination does not seem to aggravate disease activity in JIA. This indicates that the most patients with JIA can be vaccinated safely with the MMR vaccine. A prospective study is recommended.

  • measles
  • mumps and rubella vaccination
  • juvenile idiopathic arthritis
  • methotrexate
  • disease activity parameters
  • flares
View Full Text

Statistics from Altmetric.com

The pathogenesis of autoimmune disease is largely unknown.1 The association of viral infections and vaccinations with acute arthritis has led to the hypothesis that viruses such as rubella may cause chronic arthritis.2 Vaccinated healthy children were shown to experience more limb symptoms after the measles, mumps and rubella (MMR) vaccination, and a small number developed acute arthritis.3 The meningococcal C, influenza and hepatitis B vaccines seem to be safe to use in patients with juvenile idiopathic arthritis (JIA) and rheumatoid arthritis (RA).46

There are case reports of chronic arthropathy induced by rubella vaccination, but controlled studies have failed to establish this association.7 8 The MMR vaccination is included in the Dutch vaccination programme at 14 months and as a booster at 8–10 years.9 Guidelines state that live vaccines are contraindicated in patients using immunosuppressive drugs.10 Moreover, decreasing herd immunity renders patients at increased risk for naturally acquired infections, as illustrated by the recent mumps epidemic in the USA.11

To date, no evidence exists on the safety MMR vaccination in patients with JIA. The aim of the present retrospective cohort study was to investigate the effect of the MMR booster vaccination on disease course in patients with JIA.

PATIENTS AND METHODS

Patients

In total, 413 patients with JIA born between 1989 and 1996 were eligible (see supplementary figure 1, available online at http://ard.bmj.com/supplemental). We confirmed the diagnosis according to International League of Associations for Rheumatology (ILAR) criteria, but human leucocyte antigen B27 typing was performed only in 111.12 All patients were asked for the vaccination date, and to comment on side-effects after vaccination, such as clinically overt measles, and on reasons for refusing vaccination. We retrieved missing vaccination dates from the National Vaccination Institute.

Figure 1 Differences (open triangles) in disease activity criteria before and after the MMR vaccination in the whole group. Mean values in 6 months before the MMR were subtracted from the mean values after. ESR, erythrocyte sedimentation rate; PGA, physician’s global assessment.

Disease activity and medication use

Disease activity was measured as the number of joints with active arthritis, the Physician’s global assessment (PGA) of disease activity on a 3-cm visual analogue scale (VAS), and the erythrocyte sedimentation rate (ESR).13 We measured limitation of movement in the joints included in the Paediatric Escola Paulista de Medicina range of motion score.14 As expected in a retrospective study, there were many missing values for the Childhood Health Assessment Questionnaire (CHAQ) and this was therefore not analysed. Patients who did not consult their physician were assumed to have stable disease activity.

We compared the number of flares in the 6 months before and after MMR. A flare was defined as a worsening of ⩾40% in ⩾2 disease activity parameters without a simultaneous improvement of ⩾30% in ⩾2 of the remaining parameters.15 Medication use was noted for each visit.

Statistical methods

The mean of each individual disease parameter and the number of flares in the 6 months before MMR was compared with disease activity in the 6 months after MMR, using the Wilcoxon signed rank test for paired samples. We then compared disease activity in patients vaccinated between 8 and 9 years of age (group A, n = 108) with activity in children eligible to receive the MMR vaccine but who had not yet been vaccinated (group B, n = 86). Comparison of baseline characteristics between groups was calculated using the Mann–Whitney U test (two-tailed). Influence of MMR vaccination on the risk of active disease was calculated using logistic regression. Adjustments for the covariates of JIA type and medication use were made using the propensity score.16

RESULTS

Demographics

Of 413 eligible patients, 159 (38%) were excluded. In total, 59 of these did receive an MMR booster, but we were unable to retrieve their exact vaccination dates; 23 patients did not reply or had moved elsewhere; 14 patients had visited outpatient clinics elsewhere; 3 patients refused to participate; and 60 patients who developed JIA at any time point after the MMR booster were also excluded. Only one patient developed JIA within 1 month after vaccination.

Of 254 included patients, 47 had not received the MMR vaccination and were excluded. The reasons for not receiving vaccination were: doctor’s advice (n = 27), fear of side effects (n = 4), reasons of principle (n = 3), and practical reasons (n = 5). The 207 vaccinated patients with JIA had the following subtypes: persistent oligoarthritis (n = 101), extended oligoarthritis (n = 22), RF-negative polyarthritis (n = 55), RF-positive polyarthritis (n = 5), systemic arthritis (n = 17), enthesitis related arthritis (n = 3) and psoriatic arthritis (n = 4) (supplementary tables 1 and 2; available online at http://ard.bmj.com/supplemental).

Table 1 Disease activity before and after the patients with juvenile idiopathic arthritis using methotrexate, who received the measles, mumps and rubella vaccination (n = 49)
Table 2 Adjusted and non-adjusted risk of disease activity and flares in patients with juvenile idiopathic arthritis, who received the measles, mumps and rubella vaccination

Side effects

Nine patients had experienced joint complaints or aggravation of disease. Fever or general malaise was noted in six patients and two reported skin rash. No measles, mumps or rubella infections were reported. This was also true for patients using methotrexate.

Before versus after analysis

No worsening of mean disease activity parameters was seen during the 6 months after compared with the 6 months before the MMR (figure 1). In total, 40 flares occurred in 36 patients before the MMR versus 56 flares in 50 patients after the MMR (supplementary table 2; available online at http://ard.bmj.com/supplemental). This difference was not significant. Ten flares (4.8% of all patients) were seen in the first month after vaccination.

Medication use

No increase was observed in the number of patients using oral or intra-articular steroids or methotrexate. The mean dose of methotrexate or oral steroids after vaccination was also unchanged (supplementary table 2; available online at http://ard.bmj.com/supplemental).

Subgroup of vaccinated patients using methotrexate

Most of the patients using methotrexate at time of vaccination (51%) had polyarticular arthritis. As expected, baseline disease activity criteria were higher in the methotrexate group (p<0.01) More patients in the methotrexate group also used non-steroidal anti-inflammatory drugs (NSAIDs) (p<0.001) and oral steroids (p = 0.047). No aggravation of active joint count, PGA or ESR was seen in the vaccinated patients on methotrexate (table 1). No increase in flare occurrence and medication use was detected.

Historical randomisation analysis

Except for the number of limited joints, patients in group A had higher baseline disease activity (supplementary table 3, available online at http://ard.bmj.com/supplemental). There were more polyarticular patients (35.2% versus 24.4%) and fewer patients with persistent oligoarticular propblems (42.6% versus 59.3%) in group A, and relatively more patients in this group used methotrexate (23.8% versus 12.7%) and NSAIDs (50.5% versus 36.6%). Mean methotrexate dose was higher in group A, although this was not significant. From these data, we can conclude that the patients in group A had higher disease activity than those in group B.

Adjusted for JIA type and medication, the MMR vaccination did not increase the risk for an elevated active or limited joint count, PGA, ESR (table 2), or flare (odds ratio = 1.4, 95% CI 0.7 to 2.9), although all odds ratios were >1, indicating a possible increased risk of active disease.

DISCUSSION

This study shows that the MMR vaccination appears to be safe in JIA. We detected no changes in disease activity, flare occurrence or medication use after the MMR vaccination. No overt measles infections were noted. After adjustments for the possible confounders of JIA type and medication use, risk of active disease was not significantly increased in the vaccinated patients.

The main reason for exclusion was inability to retrieve the exact vaccination date (14.3% of patients). Patients with less severe disease are more likely to have no follow-up data. However, we had to exclude only 3.3% of the total population for this reason. The 47 patients who did not received the MMR vaccination tended to have more severe disease or used anti-tumour necrosis factor α therapy, so our results are not applicable to those patients with JIA. However, 49 patients using methotrexate at time of vaccination showed no aggravation of disease.

Of the 60 patients that were diagnosed after the MMR, only one developed JIA within 1 month of vaccination. A temporal relation between the MMR vaccination and JIA onset seems more likely than a causal relationship for several reasons. Firstly, cases of JIA with a disease onset >3 months after the MMR vaccination are unlikely to be related to the vaccination. Secondly, the age at onset of JIA varies between 1 and 16 years. There was no increase in the number of JIA diagnoses made shortly after vaccination. The distribution of age at onset in our population is similar to that of a cohort of patients with JIA from Sweden, where children are vaccinated at 2–12 years of age.17 Finally, a decrease in incidence of JIA was observed in the decades after introduction of the routine MMR vaccination.18

Given the retrospective nature of this study, the number of visits per patient varied. CHAQs were not routinely obtained for each visit. Therefore, we used an adjusted flare definition that does not require all six criteria. As PGA and active joints are the strongest indicators for disease activity,19 we were able to detect flares using these parameters.

As a substitute for randomisation, we developed a ”quasi-randomised” historical cohort. Although the allocation of the MMR vaccination is random, more patients with polyarticular disease were seen in the vaccinated group and more patients with oligoarticular disease in the group that had not yet been vaccinated. This indicates that the time of vaccination receipt was independent of disease type or severity. This strengthens our analysis, as confounding by indication was highly unlikely. We were able to adjust for JIA type and medication use by propensity scoring, a method for bias reduction in a non-randomised control group. Unfortunately, it was not possible to adjust for differences in baseline core set criteria. As a result, it is likely that there is residual bias in our dataset for which we could not correct. This residual bias can explain the raised odds ratios for disease activity after vaccination. However, we cannot fully rule out that there was a small influence of the MMR vaccination on disease activity. Even though this was one of the largest cohorts of vaccinated patients with JIA, we realise that its statistical power is limited. To further ascertain safety and efficacy of the MMR vaccination in JIA, a prospective trail is recommended.

Supplementary material can be viewed online on the ARD website at http://ard.bmj.com/supplemental.

Acknowledgments

We thank Petra Oomen (National Vaccination Institute), Jan Jaap van der Net and Mirjam Visser (Wilhelmina Children’s Hospital) for providing patient data. Nico Wulffraat was supported by the Dutch League against Rheumatism. Mare Pileggi was supported by the ALFA project from the Pediatric Rheumatology International Trial Organisation.

REFERENCES

View Abstract

Footnotes

  • Competing interests: None declared.

  • Abbreviations:
    CHAQ
    Childhood Health Assessment Questionnaire
    DMARD
    disease-modifying anti-rheumatic drug
    ESR
    erythrocyte sedimentation rate
    ILAR
    International League of Associations for Rheumatology
    JIA
    juvenile idiopathic arthritis
    MMR
    measles, mumps and rubella
    NSAID
    non-steroidal anti-inflammatory drug
    PGA
    physician’s global assessment
    RF
    rheumatoid factor

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.